Skip to main content

Table 2 Therapeutic data and disease activity states at cross-sectional visit in patients still receiving etanercept (n = 422)a

From: Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

  No assessed No (%) positive
Concomitant therapies
 Systemic corticosteroids 422 20 (4.7)
 Intra-articular corticosteroids 422 11 (2.6)
 Methotrexate 422 200 (47.4)
 Salazopyrin 422 3 (0.7)
 Azathioprine 422 1 (0.2)
Disease activity states – Formal definitions
 Wallace criteria for inactive disease 392 164 (41.8)
 Wallace criteria for inactive disease without
 acute phase reactants
420 214 (51)
 Magni-Manzoni criteria for low disease activity 420 267 (63.6)
Disease activity states – JADAS10
 Inactive disease 422 196 (46.4)
 Low disease activityb 422 270 (64)
 Moderate disease activity 422 103 (24.4)
 High disease activity 422 49 (11.6)
Disease activity states – cJADAS10
 Inactive disease 422 205 (48.6)
 Low disease activityb 422 246 (58.3)
 Moderate disease activity 422 117 (27.7)
 High disease activity 422 59 (14)
Patients with no active joints 422 289 (68.5)
Patients with no swollen joints 422 313 (74.2)
Patients with no tender joints 422 299 (70.9)
Patients with no restricted joints 422 253 (60)
Patients with physician’s VAS = 0 422 239 (56.6)
Patients with ESR < 20 mm/h 398 321 (80.7)
Patients with normal CRP 402 341 (84.8)
Patients with JADI Articular = 0 419 324 (77.3)
Patients with JADI Extraarticular = 0 419 364 (86.9)
  1. IQR interquartile range, JADAS Juvenile Arthritis Disease Activity Score, VAS visual analog scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, JADI Juvenile Arthritis Damage Index
  2. aData are number (percentage) unless otherwise indicated
  3. bIncludes patients with inactive disease